Vibativ
Total Payments
$237,648
Transactions
1,836
Doctors
822
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $46,716 | 606 | 305 |
| 2019 | $76,147 | 990 | 511 |
| 2018 | $114,785 | 240 | 207 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $138,259 | 30 | 58.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $50,563 | 28 | 21.3% |
| Food and Beverage | $34,257 | 1,761 | 14.4% |
| Travel and Lodging | $7,892 | 11 | 3.3% |
| Grant | $2,800 | 1 | 1.2% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $2,000 | 1 | 0.8% |
| Consulting Fee | $1,875 | 3 | 0.8% |
| Education | $3.13 | 1 | 0.0% |
Payments by Type
Research
$138,259
30 transactions
General
$99,389
1,806 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Protocol 0101 | Cumberland Pharmaceuticals, Inc. | $41,902 | 0 |
| ResearchProtocol 0112 A Phase 3 Multicenter, Randomized, Open-label, Clinical Trial of Telavancin Versus Standard Intravenous Therapy Nov 23, 2018 | Cumberland Pharmaceuticals, Inc. | $22,582 | 0 |
| ResearchProtocol 0112 A Phase 3 Multicenter, Randomized, Open-label, Clinical Trial of Telavancin Versus Standard Intravenous Therapy Nov 28, 2018 | Cumberland Pharmaceuticals, Inc. | $21,435 | 0 |
| ResearchProtocol 0112 Dec 07, 2018 | Cumberland Pharmaceuticals, Inc. | $15,016 | 0 |
| ResearchPharmacokinetics and Tolerability of TLVN at Differing Dosing Regimens in Cystic Fibrosis Adults Dec 03, 2018 | Cumberland Pharmaceuticals, Inc. | $12,631 | 0 |
| ResearchProtocol 0112 A Phase 3 Multicenter, Randomized, Open-label, Clinical Trial of Telavancin Versus Standard Intravenous Therapy Nov 20, 2018 | Cumberland Pharmaceuticals, Inc. | $11,044 | 0 |
| ResearchTLVN.6424.PH4 THX0101 Dec 11, 2018 | Cumberland Pharmaceuticals, Inc. | $5,276 | 0 |
| ResearchProtocol 0112 A Phase 3 Multicenter, Randomized, Open-label, Clinical Trial of Telavancin Versus Standard Intravenous Therapy Nov 16, 2018 | Cumberland Pharmaceuticals, Inc. | $3,748 | 0 |
| SYNEOSAug2019Protocol0112 | Cumberland Pharmaceuticals, Inc. | $3,400 | 0 |
| ResearchProtocol 0112 Dec 08, 2018 | Cumberland Pharmaceuticals, Inc. | $975.00 | 1 |
| ResearchProtocol 0112 Jan 26, 2019 | Cumberland Pharmaceuticals, Inc. | $250.00 | 0 |
Top Doctors Receiving Payments for Vibativ
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Sacramento, CA | $140,084 | 30 |
| , MD | Infectious Disease | Huntsville, AL | $12,046 | 10 |
| , MD | Infectious Disease | Pittsburgh, PA | $9,356 | 27 |
| , M.D | Specialist | Plymouth, MI | $6,000 | 4 |
| , M.D | Infectious Disease | Temecula, CA | $5,923 | 12 |
| , MD, MPH | Infectious Disease | Sacramento, CA | $5,711 | 5 |
| , M.D | Infectious Disease | Bridgeport, WV | $4,642 | 20 |
| , MD | Infectious Disease | Austin, TX | $4,401 | 13 |
| , DO | Infectious Disease | Greenville, NC | $4,138 | 5 |
| , MD | Infectious Disease | The Woodlands, TX | $2,291 | 17 |
| , M.D | Infectious Disease | Las Vegas, NV | $2,236 | 9 |
| , MD | Infectious Disease | Memphis, TN | $2,200 | 4 |
| , MD | Infectious Disease | Memphis, TN | $1,631 | 3 |
| , M.D.P.A | Infectious Disease | Jersey City, NJ | $1,568 | 8 |
| , M.D | Pulmonary Disease | East Setauket, NY | $1,032 | 5 |
| , D.O | Internal Medicine | Laguna Hills, CA | $975.00 | 1 |
| , MD | Infectious Disease | Columbus, OH | $875.00 | 1 |
| , M.D | Infectious Disease | Dallas, TX | $500.00 | 1 |
| , MD | Internal Medicine | Louisville, KY | $359.95 | 5 |
| , MD | Obstetrics & Gynecology | Riverside, CA | $342.94 | 13 |
| , MD | Infectious Disease | The Woodlands, TX | $290.52 | 16 |
| , MD | Infectious Disease | Dallas, TX | $282.56 | 18 |
| , MD | Infectious Disease | Fayetteville, NC | $281.14 | 23 |
| , MD, MS | Internal Medicine | Omaha, NE | $265.89 | 16 |
| , MD | Internal Medicine | Boca Raton, FL | $230.40 | 18 |
Ad
Manufacturing Companies
- Cumberland Pharmaceuticals, Inc. $237,648
Product Information
- Type Drug
- Total Payments $237,648
- Total Doctors 822
- Transactions 1,836
About Vibativ
Vibativ is a drug associated with $237,648 in payments to 822 healthcare providers, recorded across 1,836 transactions in the CMS Open Payments database. The primary manufacturer is Cumberland Pharmaceuticals, Inc..
Payment data is available from 2018 to 2020. In 2020, $46,716 was paid across 606 transactions to 305 doctors.
The most common payment nature for Vibativ is "Unspecified" ($138,259, 58.2% of total).
Vibativ is associated with 11 research studies, including "Protocol 0101" ($41,902).